Muscle as a metabolic factory for gene therapy

Muscle Gene Therapy

Volumn , Issue , 2010, Pages 219-230

  Mah, Cathryn S ^a   Pacak, Christina A ^a   Byrne, Barry J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919839628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-1207-7_13     Document Type: Chapter

References (50)

1. Angelos, S., Valberg, S. J., Smith, B. P., McQuarrie, P. S., Shanske, S., Tsujino, S., Di Mauro, S., Cardinet, G. H., III (1995). Myophosphorylase deficiency associated with rhabdomyolysis and exercise intolerance in 6 related Charolais cattle. Muscle Nerve 18, 736-740.
2. Arruda, V. R., Schuettrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., High, K. A. (2004). Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103, 85-92.
3. Arruda, V. R., Stedman, H. H., Nichols, T. C., Haskins, M. E., Nicholson, M., Herzog, R. W., Couto, L. B., High, K. A. (2005). Regional intravascular delivery of AAV-2-F. IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105, 3458-3464.
4. Baque, S., Newgard, C. B., Gerard, R. D., Guinovart, J. J., Gomez-Foix, A. M. (1994). Adenovirusmediated delivery into myocytes of muscle glycogen phosphorylase, the enzyme deficient in patients with glycogen-storage disease type V. Biochem J 304, 1009-1014.
5. Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 106, 16363-16368.
6. Brantly, M. L., Spencer, L. T., Humphries, M., Conlon, T. J., Spencer, C. T., Poirier, A., Garlington, W., Baker, D., Song, S., Berns, K. I., Muzyczka, N., Snyder, R. O., Byrne, B. J., Flotte, T. R. (2006). Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 17, 1177-1186.
7. Cresawn, K. O., Fraites, T. J., Wasserfall, C., Atkinson, M., Lewis, M., Porvasnik, S., Liu, C., Mah, C., Byrne, B. J. (2005). Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum. Gene Ther 16, 68-80.
8. Dimaur, S., Andreu, A. L., Bruno, C., Hadjigeorgiou, G. M. (2002). Myophosphorylase deficiency (glycogenosis type V; McArdle disease). Curr Mol Med 2, 189-196.
9. Ding, E., Hu, H., Hodges, B. L., Migone, F., Serra, D., Xu, F., Chen, Y. T., Amalfitano, A. (2002). Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 5, 436-446.
10. Douillard-Guilloux, G., Raben, N., Takikita, S., Batista, L., Caillaud, C., Richard, E. (2008). Modulation of glycogen synthesis by RNA interference: Towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet 17, 3876-3886.
11. Fraites, T. J., Jr., Schleissing, M. R., Shanely, R. A., Walter, G. A., Cloutier, D. A., Zolotukhin, I., Pauly, D. F., Raben, N., Plotz, P. H., Powers, S. K., Kessler, P. D., Byrne, B. J. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5, 571-578.
12. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., Wilson, J. M. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99, 11854-11859.
13. Haller, R. G. (2000). Treatment of McArdle disease. Arch Neurol 57, 923-924.
14. Hauck, B., Xiao, W. (2003). Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 77, 2768-2774.
15. Hirschhorn, R., Reuser, A. J. J. (2000). Glycogen storage disease II: Acid-alpha glucosidase (acid maltase) deficiency. In: Metabolic Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, eds. (New York: McGraw Hill), pp. 3389-3420.
16. Hoefsloot, L. H., Willemsen, R., Kroos, M. A., Hoogeveen-Westerveld, M., Hermans, M. M., Van Der Ploeg, A. T., Oostra, B. A., Reuser, A. J. (1990). Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J 272, 485-492.
17. Howell, J. M., Walker, K. R., Davies, L., Dunton, E., Everaardt, A., Laing, N., Karpati, G. (2008). Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: Expression and reexpression of glycogen phosphorylase. Neuromuscul Disord 18, 248-258.
18. Jiang, H., Pierce, G. F., Ozelo, M. C., De Paula, E. V., Vargas, J. A., Smith, P., Sommer, J., Luk, A., Manno, C. S., High, K. A., Arruda, V. R. (2006). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14, 452-455.
19. Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., Tai, S. J., Herzog, R. W., Arruda, V., Johnson, F., Scallan, C., Skarsgard, E., Flake, A. W., High, K. A. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24, 257-261.
20. Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., Byrne, B. J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93, 14082-14087.
21. Kishnani, P. S., Hwu, W. L., Mandel, H., Nicolino, M., Yong, F., Corzo, D. (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148, 671-676.
22. Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., Li, J., Dumontier, J., Halberthal, M., Chien, Y. H., Hopkin, R., Vijayaraghavan, S., Gruskin, D., Bartholomew, D., Van Der, P. A., Clancy, J. P., Parini, R., Morin, G., Beck, M., De La Gastine, G. S., Jokic, M., Thurberg, B., Richards, S., Bali, D., Davison, M., Worden, M. A., Chen, Y. T., Wraith, J. E. (2007). Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99-109.
23. Lin, C. Y., Ho, C. H., Hsieh, Y. H., Kikuchi, T. (2002). Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Ther 9, 554-563.
24. Mah, C., Cresawn, K. O., Fraites, T. J., Jr., Pacak, C. A., Lewis, M. A., Zolotukhin, I., Byrne, B. J. (2005). Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12, 1405-1409.
25. Mah, C., Pacak, C. A., Cresawn, K. O., Deruisseau, L. R., Germain, S., Lewis, M. A., Cloutier, D. A., Fuller, D. D., Byrne, B. J. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 15, 501-507.
26. Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., Kay, M. A., High, K. A., Glader, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972.
27. Martin-Touaux, E., Puech, J. P., Chateau, D., Emiliani, C., Kremer, E. J., Raben, N., Tancini, B., Orlacchio, A., Kahn, A., Poenaru, L. (2002). Muscle as a putative producer of acid alphaglucosidase for glycogenosis type II gene therapy. Hum Mol Genet 11, 1637-1645.
28. McArdle, B. (1951). Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 10, 13-33.
29. Mueller, C., Flotte, T. R. (2008). Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 35, 164-178.
30. Muscular Dystrophy Association (2009). McArdle disease factsheet. [http://www.muscular-dystrophy.org/information-resources/factsheets/medical-conditions-factsheets/mcardles.html.
31. Nogales-Gadea, G., Arenas, J., Andreu, A. L. (2007). Molecular genetics of McArdle's disease. Curr Neurol Neurosci Rep 7, 84-92.
32. Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., Byrne, B. J. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99, e3-e9.
33. Pari, G., Crerar, M. M., Nalbantoglu, J., Shoubridge, E., Jani, A., Tsujino, S., Shanske, S., Di Mauro, S., Howell, J. M., Karpati, G. (1999). Myophosphorylase gene transfer in McArdle's disease myoblasts in vitro. Neurology 53, 1352-1354.
34. Pauly, D. F., Johns, D. C., Matelis, L. A., Lawrence, J. H., Byrne, B. J., Kessler, P. D. (1998). Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther 5, 473-480.
35. Pauly, D. F., Fraites, T. J., Toma, C., Bayes, H. S., Huie, M. L., Hirschhorn, R., Plotz, P. H., Raben, N., Kessler, P. D., Byrne, B. J. (2001). Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum Gene Ther 12, 527-538.
36. Phoenix, J., Hopkins, P., Bartram, C., Beynon, R. J., Quinlivan, R. C., Edwards, R. H. (1998). Effect of vitamin B6 supplementation in McArdle's disease: A strategic case study. Neuromuscul Disord 8, 210-212.
37. Raben, N., Lu, N., Nagaraju, K., Rivera, Y. Lee, A., Yan, B., Byrne, B., Meikle, P. J., Umapathysivam, K., Hopwood, J. J., Plotz, P. H. (2001). Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy. Hum Mol Genet 10, 2039-2047.
38. Raben, N., Plotz, P., Byrne, B. J. (2002). Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2, 145-166.
39. Raben, N., Fukuda, T., Gilbert, A. L., De, J. D., Thurberg, B. L., Mattaliano, R. J., Meikle, P., Hopwood, J. J., Nagashima, K., Nagaraju, K., Plotz, P. H. (2005). Replacing acid alpha-glucosidase in Pompe disease: Recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11, 48-56.
40. Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., Samulski, R. J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple A AV serotypes enables transduction with broad specificity. J Virol 76, 791-801.
41. Schoser, B., Hill, V. Raben, N. (2008). Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics 5, 569-578.
42. Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y. T., Koeberl, D. D. (2005). Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 11, 57-65.
43. Sun, B., Young, S. P., Li, P., Di, C., Brown, T., Salva, M. Z., Li, S., Bird, A., Yan, Z., Auten, R., Hauschka, S. D., Koeberl, D. D. (2008). Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 16, 1366-1371.
44. Tan, P., Allen, J. G., Wilton, S. D., Akkari, P. A., Huxtable, C. R., Laing, N. G. (1997). A splice-site mutation causing ovine McArdle's disease. Neuromuscul Disord 7, 336-342.
45. Tsujino, S., Kinoshita, N., Tashiro, T., Ikeda, K., Ichihara, N., Kikuchi, H., Hagiwara, Y. Mizutani, M., Kikuchi, T., Sakuragawa, N. (1998). Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum Gene Ther 9, 1609-1616.
46. Vorgerd, M., Grehl, T., Jager, M., Muller, K., Freitag, G., Patzold, T., Bruns, N., Fabian, K., Tegenthoff, M., Mortier, W., Luttmann, A., Zange, J., Malin, J. P. (2000). Creatine therapy in myophosphorylase deficiency (McArdle disease): A placebo-controlled crossover trial. Arch Neurol 57, 956-963.
47. Wisselaar, H. A., Kroos, M. A., Hermans, M. M., Van, B. J., Reuser, A. J. (1993). Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268, 2223-2231.
48. Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., Wilson, J. M. (1999). Gene therapy vectors based on adeno-associated virus type 1. J Virol 73, 3994-4003.
49. Zaretsky, J. Z., Candotti, F., Boerkoel, C., Adams, E. M., Yewdell, J. W., Blaese, R. M., Plotz, P. H. (1997). Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum Gene Ther 8, 1555-1563.
50. Ziegler, R. J., Bercury, S. D., Fidler, J., Zhao, M. A., Foley, J., Taksir, T. V., Ryan, S., Hodges, B. L., Scheule, R. K., Shihabuddin, L. S., Cheng, S. H. (2008). Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 19, 609-621.